IPHARMA obtained an approval to conduct the clinical trial of a drug against COVID-19

IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct a Phase II clinical trial of the drug CKD-506.


The investigational drug developer is the Chong Kun Dang Pharmaceutical Corp. (Republic of Korea).

Protocol № А82_02CVD2021 "Randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of CKD-506 in hospitalized adult patients diagnosed with COVID-19 pneumonia".


The purpose is to evaluate the efficacy and safety of CKD-506 in hospitalized adult patients diagnosed with COVID-19 pneumonia.


The study will be conducted in 29 clinical sites in 15 cities.


Недавние посты
Архив

© 2021 IPHARMA

  • Facebook Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon